In 2005 the European Respiratory Society (ERS), in collaboration with The European Society for Clinical Microbiology and Infectious Diseases (ESCMID), published guidelines on the management of lower respiratory tract infections (LRTI) in adults [1]. This document was based on published scientific literature up to the end of 2002. We have now updated these guidelines to include publications to May 2010. The Taskforce responsible for guideline development has been sponsored by the ERS and ESCMID. Members of the Taskforce are members of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI. The target audience for the guidelines is thus all those whose routine practice includes the management of adult LRTI.
This document begins with definitions and background sections on microbial cause, resistance and pharmacokinetics/pharmacodynamics, with conventional referencing. The guideline section captures management outside hospital, management inside hospital (including community-acquired pneumonia (CAP), acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and acute exacerbations of bronchiectasis) and prevention. The guidelines are about the management of infection. This means that for conditions such as AECOPD, aspects of management that are unreleated to infection (e.g. use of steroids or bronchodilators) are not included. It contains the graded recommendations but also the background information for each recommendation, with details about each new cited reference and the evidence grades. Because this is an update, original data and publications have usually not been repeated and the reader is referred to the original publication for this. As this is an update using the same methodologies, the layout of the document, including text, recommendations and evidence tables, is the same as in 2005.
下呼吸道感染吃什么药 2011欧洲下呼吸道感染攻略
精彩推荐
- 从“可用”到“好用且安全”:华为乾崑智驾ADS 4的进阶逻辑

在智能驾驶技术加速落地的今天,行业正面临一个关键命题:如何让辅助驾驶真正从能用跨越到好用且安全?市场上不乏宣称具备高阶智驾能力的产品,但多数仍停留在特定场景下的...详细
- 月销超30万辆、新能源17.8万辆齐创新高,吉利汽车集团为杭马注入中国智造力量

2025年11月2日,吉利汽车2025杭州马拉松在黄龙体育中心正式鸣枪开跑,3万多名跑者参与赛事,用奔跑串联西湖与钱塘江的千年文脉。作为赛事冠名合作伙伴,吉利汽车集团以10月...详细
- 迈向健康新时代:“酶好时光”全国启动大会在嘉兴举行,开启生命科学赋能全民健康新篇章

在生命科学日益成为推动人类健康进步核心动力的今天,健康产业正经历从宏观养护向微观精准干预的历史性跨越。10月26日,以酶好时光为主题的大型全国启动大会在浙江嘉兴隆重...详细
- 口碑验证产品力,权益彰显诚意!问界新M5 Ultra销量稳居高位

在竞争日趋白热化的智能SUV市场,销量数据往往最能说明问题。问界新M5 Ultra用实实在在的市场表现证明了其过硬的产品力,自问界新M5 Ultra今年4月单月销量突破4000辆后,5...详细
本周热门
- 同仁堂健康双十一活动开启 “象食养医”倡导从健康的时候就关注健康

如果你想了解自己身体的秘密,让健康成为日常的生活方式,保持年轻的状态,实现抗衰老,逆生长的美好愿望,那么今年双十一的这场活动你一定不要错过。11月1日,同仁堂健康...详细





